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Background: The cirrhosis complications hepatic encephalopathy, ascites, and variceal bleeding increase mortality
but develop in random sequence. Therefore prognoses based on the presence or absence of these clinical
complications are inherently inaccurate, and other determinants of the clinical course should be identified. Here we
present our study of patho-etiological factors that may be causally involved in the development of specific
complications to alcoholic cirrhosis; it was based on a model of cirrhosis pathophysiology encompassing hepatic
metabolic capacity, continued alcohol consumption, and circulatory dysfunction.
Methods: We followed a Danish community-based cohort of 466 patients with alcoholic cirrhosis. Stratified Cox
regression was used to examine the effects of GEC (a measure of hepatic metabolic capacity), alcohol consumption,
and plasma sodium concentration (a measure of circulatory dysfunction) on the hazard rates of first-time hepatic
encephalopathy, first-time ascites, first-time variceal bleeding, and mortality. We adjusted for confounding by
comorbidity, gender, and age. Data on risk factors and confounders were updated during follow-up.
Results: A low GEC increased the risk of first-time hepatic encephalopathy (hazard ratio [HR] 1.21 per 0.1 mmol/min
GEC loss, 95% CI 1.11-1.31), but was unassociated with other adverse events. Alcohol consumption increased the
risk of first-time ascites (HR 3.18, 95% CI 1.19-8.47), first-time variceal bleeding (HR 2.78, 95% CI 1.59-4.87), and
mortality (HR 2.45, 95% CI 1.63-3.66), but not the risk of first-time hepatic encephalopathy. Hyponatremia increased
the risk of all adverse events.
Conclusions: Reduced hepatic metabolic capacity, alcohol consumption, and hyponatremia were causally involved
in the development of specific complications to alcoholic cirrhosis.
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We recently described the development of hepatic en-
cephalopathy, ascites, and variceal bleeding in Danish
patients with alcoholic cirrhosis [1]. The appearance of
these complications increased mortality, but they devel-
oped in random sequence. Therefore mortality predic-
tions based solely on their presence or absence are
inherently inaccurate, and other determinants of the
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reproduction in any medium, provided the orCirrhosis patients have reduced hepatic metabolic cap-
acity, and the residual capacity can be measured with the
galactose elimination capacity (GEC) test [2], the result
of which is a strong predictor of mortality [3]. Some
patients with alcoholic cirrhosis continue drinking alco-
hol, and such exposure to the etiology of their disease
increases mortality [4]. Finally, cirrhosis is accompanied
by renal dysfunction and water dyshomeostasis causing
hyponatremia which is associated with increased mortal-
ity [5]. We examined whether those three patho-
etiological factors—reduced hepatic metabolic capacity,
continued alcohol consumption, and circulatory dysfunc-
tion—are causally involved in the development of specific
complications to alcoholic cirrhosis, and not merelyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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on a model of cirrhosis pathophysiology restricted to the
three patho-etiological factors and relevant confounders,
and we aimed to establish causal links between the
pathophysiology and the clinical course of alcoholic
cirrhosis.
Methods
We followed a community-based cohort of 466 Danish
citizens who resided in our hospital’s catchment area
and were diagnosed with alcoholic cirrhosis between 1
January 1993 and 31 August 2005 and had not previ-
ously been examined for suspected cirrhosis. Thirty
patients (6%) were diagnosed on the basis of liver biopsy
findings, the remainder on the basis of clinical, biochem-
ical, imaging, and hemodynamic findings. Six patients
received a liver transplant [1]. According to Danish law,
registry-based studies such as this require neither ethical
approval nor patient consent.
Galactose elimination capacity, alcohol consumption, and
plasma sodium concentration
The GEC is a physiological measure of hepatic metabolic
capacity and is part of our clinical workup of patients
with cirrhosis [2,3]. We obtained the results of all GEC
tests conducted during the follow-up period from our
department’s laboratory database. Data on patients’ alco-
hol consumption were obtained from the medical charts.
We recorded patients’ current alcohol drinking status
(abstinent or drinking) as reported at each hospital con-
tact. Abstinence was defined as complete abstinence or
consumption of small amounts of alcohol on rare occa-
sions. Drinking was defined as non-abstinence. Plasma
sodium concentrations were measured frequently in
both in- and outpatients, and we extracted all measure-
ments from the database of the department of clinical
biochemistry.
Confounders: comorbidity, gender, and age
Comorbidity, male gender, and older age increase mor-
tality among cirrhosis patients [6,7], and these factors
are also associated with hepatic metabolic capacity [3].
They were therefore considered potential confounders of
the associations of interest in this study. Information on
patients’ comorbidities were extracted from the Danish
National Patient Registry and scored with the Charlson
Comorbidity Index (CCI), which assigns a weight to
chronic diseases according to their impact on mortality
[6]. Comorbidities diagnosed during follow-up were
added to the CCI from their date of diagnosis.
Outcome events
We examined four outcome events: first-time hepatic
encephalopathy, first-time ascites, first-time varicealbleeding, and death. Data were obtained from the
patients’ medical charts and from the Danish Civil Regis-
tration System which is continuously updated with dates
of birth, death, and migration for the Danish population
[8]. Hepatic encephalopathy was defined as overt hepatic
encephalopathy, and ascites was defined as clinically de-
tectable ascites, i.e., ascites detected only on ultrasound
examination was excluded. Variceal bleeding was defined
as clinically unequivocal bleeding from esophageal or
gastric varices with hematemesis in combination with a
heart rate >100 beats per minute and systolic blood
pressure <100 mmHg or a need for blood transfusion.
Statistical analysis
We conducted four separate analyses to examine the risk
factors for the four events of interest. In each analysis the
patients were followed from the diagnosis of cirrhosis
until they experienced the event. Event-free patients were
censored on 31 August 2006, and—in the three analyses
with a complication as the event of interest—also at
death. We used stratified Cox proportional hazards re-
gression with GEC, alcohol consumption, plasma sodium
concentration, CCI, and age as time-dependent variables
[9], gender as a time-fixed variable, and the patients’
current complications as time-dependent strata. The
stratification implied the assumption that, for example,
patients with hepatic encephalopathy and patients with
ascites had different mortality rates (and patients with
variceal bleeding or no complications had yet other mor-
tality rates), but a 0.1 mmol/min GEC loss had the same
multiplicative effect on everybody’s mortality rate. Not all
patients had a GEC test, so the analyses were conducted
with and without GEC included in the regression model.
In the analyses including GEC we included only patients
who had a GEC test within 30 days after cirrhosis diag-
nosis, and patients were followed from the date of the
GEC test. Effect estimates whose 95% confidence interval
excluded the null value were considered statistically sig-
nificant. The assumption of proportional hazards was
tested with Schoenfeld residuals against follow-up time
and was not violated.
Results
The study comprised 466 newly diagnosed alcoholic cir-
rhosis patients: 114 (24%) without complications, 19
(4.1%) with hepatic encephalopathy alone, 254 (55%)
with ascites alone, 29 (6.2%) with variceal bleeding alone,
23 (4.9%) with hepatic encephalopathy and ascites,
2 (0.4%) with hepatic encephalopathy and variceal
bleeding, 20 (4.3%) with ascites and variceal bleeding,
and 5 (1.1%) with all three complications. Hence,
114 + 254 + 29 + 20 = 417 patients did not have hepatic
encephalopathy and were consequently at risk of first-
time hepatic encephalopathy; similarly, 164 patients were
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of first-time variceal bleeding (Table 1).
A low GEC increased the risk of first-time hepatic en-
cephalopathy (adjusted hazard ratio = 1.21 per 0.1 mmol/
min GEC loss, 95% CI = 1.11-1.31), but did not affect the
risk of first-time ascites or first-time variceal bleeding or
increase mortality. Alcohol consumption had opposite
effects, i.e., it was not a risk factor for first-time hepatic
encephalopathy but increased the risks of first-time asci-
tes, first-time variceal bleeding, and mortality. Hypona-
tremia was a risk factor for all three complications and
also increased mortality. Associations were the same in
the full cohort and in the subcohort with a GEC test
(Table 2).
Discussion
Our community-based study of 466 patients with newly
diagnosed alcoholic cirrhosis supported our hypothesis
that patho-etiological factors are causally involved in the
development of specific complications. In particular,
reduced hepatic metabolic capacity was specifically asso-
ciated with the risk of developing first-time hepatic en-
cephalopathy. Alcohol consumption increased the risk of
all adverse events except the development of first-time
hepatic encephalopathy. Hyponatremia, by increasing
the risk of all complications as well as mortality, was a
non-specific marker of a poor prognosis.Table 1 Patient characteristics at diagnosis of alcoholic cirrho
At risk of first-time
hepatic encephalopath
Number of patients 417
Total follow-up time 1481 years




Variceal bleeding 49 (12%)
GEC, median (25th – 75th percentile) 1.59 (1.36-1.88)
Alcohol consumers (%) 327 (78%)
Plasma sodium, median (25th – 75th percentile) 136 (132–139)
Charlson Comorbidity Index > 0 157 (38%)
Age, median (25th – 75th percentile) 51 (45–60)
Men (%) 295 (71%)
Events during follow-up
First-time hepatic encephalopathy 120 (29%)#
First-time ascites 45 (11%)
First-time variceal bleeding 78 (19%)
Death 150 (36%)
† Patients may have more than one complication.
# Follow-up stopped when this event occurred.The major strength of our study is that it was designed
to evaluate hypotheses about the causal effects of
reduced hepatic metabolic capacity, continued alcohol
consumption, and hyponatremia on the development of
complications—not merely to examine whether they pre-
dict their development. A clear distinction between
causes and predictors is necessary in order to advance
our understanding of cirrhosis pathophysiology: A cause
is always a predictor, but a predictor can be either a
cause or a correlate of a cause, an ‘innocent bystander’
[10]. A composite score such as the MELD (Model for
Endstage Liver Disease) score is a likely predictor of cir-
rhosis progression, but the causal effect(s) of a high
MELD score are unclear because it may represent a loss
of kidney function (high creatinine), a loss of hepatic
synthetic capacity (high INR), and/or a loss of hepatic
conjugative capacity (high bilirubin). Therefore we did
not include the MELD score in our analyses. Nor did we
include its components or other standard liver biochem-
istry tests because they correlate with the GEC but are
not truly tests of hepatic metabolic capacity [11].
Given this background, our findings are consistent
with the definition that loss of hepatic metabolic cap-
acity is a prerequisite for developing hepatic encephalop-
athy [12], but we add that loss of hepatic metabolic
capacity does not cause death without hepatic encephal-
opathy. This novel finding expands upon our previoussis
y
At risk of first-time
ascites




553 years 1420 years 1611 years
114 (70%) 114 (28%) 114 (24%)
21 (13%) 42 (10%) 49 (11%)
- 277 (68%) 302 (65%)
31 (19%) - 56 (12%)
1.75 (1.48-2.06) 1.55 (1.34-1.79) 1.56 (1.35-1.86)
124 (76%) 313 (76%) 366 (79%)
138 (135–140) 136 (132–139) 136 (132–139)
76 (46%) 153 (37%) 177 (38%)
53 (47–61) 53 (46–61) 53 (47–61)
123 (75%) 284 (69%) 329 (71%)
19 (12%) 75 (18%) 120 (26%)
55 (34%)# 41 (10%) 55 (12%)
18 (11%) 91 (22%)# 91 (20%)
57 (35%) 192 (47%) 299 (64%)
Table 2 Effects of galactose elimination capacity, alcohol consumption, and plasma sodium concentration on the clinical course of alcoholic cirrhosis
Hepatic encephalopathy Ascites Variceal bleeding Death
All patients
at risk












Patients at risk +
with GEC test
N= 417 N=237 N=164 N=56 N=410 N=231 N=466 N=266
GEC, per 0.1
mmol/min loss
1.21 (1.11-1.31) 1.04 (0.84-1.30) 1.01 (0.95-1.08) 1.04 (0.98-1.10)
Alcohol
consumption
0.93 (0.51-1.70) 0.82 (0.45-1.50) 1.95 (1.16-3.26) 3.18 (1.19-8.47) 2.01 (1.28-3.14) 2.78 (1.59-4.87) 2.20 (1.68-2.88) 2.45 (1.63-3.66)
Plasma sodium,
per mmol/L loss
1.14 (1.10-1.19) 1.14 (1.09-1.18) 1.12 (1.05-1.20) 1.16 (1.06-1.28) 1.08 (1.05-1.11) 1.07 (1.04-1.10) 1.13 (1.11-1.15) 1.14 (1.11-1.18)
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cirrhosis patients [3]: It is now clear that loss of hepatic
metabolic capacity causes hepatic encephalopathy and
then death [1]. Our previous study suggested that a GEC
above 1.75 mmol/min was associated with a relatively fa-
vorable prognosis, whereas mortality increased linearly
with GEC when GEC fell below this limit [3]. We specu-
late that the same limit applies to the risk of hepatic en-
cephalopathy, but our current study did not have
sufficient statistical power to clarify this.
Alcohol consumption can cause ascites formation and
variceal bleeding, according to our findings. The likely
explanation is that alcohol intake induces a prompt in-
crease in portal pressure [13-15]. However, the associ-
ation might also be partly due to alcohol consumers’
noncompliance with diuretics and beta-blocker treat-
ments, i.e. non-causal. The association between alcohol
consumption and mortality was expected because alco-
holism is a risk factor for death among infected cirrho-
sis patients and for several cancers [16,17]. It is even
possible that we underestimated the adverse effects of
alcohol because we may have missed alcohol relapse in
some patients who died at home. The lack of an associ-
ation between alcohol consumption and hepatic en-
cephalopathy is consistent with findings from a
randomized clinical trial comparing porto-systemic
shunt placements. In that study, drinking spells during
follow-up were more strongly associated with variceal
bleeding and mortality than with hepatic encephalop-
athy [18].
The cirrhosis patients with hyponatremia had higher
risk of all adverse events, so these patients’ clinical
course remained as unpredictable as that of patients
without hyponatremia. Our findings are consistent with
observations that hyponatremia causes hepatic encephal-
opathy [10,19], but we might have learned more if we
had measured urinary sodium excretion which decreases
before dilutional hyponatremia develops [20]. Unfortu-
nately, it was not measured in a meaningful proportion
of our patients, and it remains possible that hyponatre-
mia is an innocent bystander rather than an agent in the
causal pathways to the development of cirrhosis
complications.
Our data had high validity. We believe that the med-
ical charts from one of Denmark’s two specialized
departments of hepatology gave reliable records of all
first-time episodes of major cirrhosis complications. The
chart data were extracted previously for a different re-
search purpose [1], so there was no bias from a con-
scious or unconscious wish to find certain associations
in the data. The absence of data on portal pressure and
medication use is a limitation of the study because both
factors modify the risk of complications and represent
distinct pathophysiological mechanisms.Conclusion
In conclusion, reduced hepatic metabolic capacity, con-
tinued alcohol consumption, and circulatory dysfunction
had distinct adverse effects on the risks of first-time hep-
atic encephalopathy, first-time ascites, first-time variceal
bleeding, and death. Our findings unite, expand, and
strengthen the findings from several previous studies on
the clinical course of cirrhosis and improve our under-
standing of the disease.
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